论文部分内容阅读
目的:探讨胸苷酸合酶(thymidylate synthase,TS)基因5’-端非编码区(5’-untranslation region,5’-UTR)变数串联重复(variable number of tandem repeat,VNTR)多态性与培美曲塞治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)疗效的相关性。方法:回顾性分析90例晚期NSCLC患者的临床参数;抽取患者外周血标本并提取DNA,通过复合扩增荧短片段重复序列聚合酶链反应(short tandem repeat-polymerase chain reaction,STR-PCR)结合毛细血管电泳的方法检测TS基因5’-UTRVNTR的多态性。结果:TS基因5’-UTRVNTR纯合状态(2R/2R+3R/3R)与杂合状态(2R/3R+3R/4R)均与培美曲塞的临床疗效无相关性,其无进展生存期分别为112d和94d(P=0.549),疾病控制率为64.3%和67.6%(P=0.745),客观缓解率为12.5%和8.8%(P=0.591);2R多态性(2R/2R+2R/3R)和3R多态性(3R/3R+3R/4R)亦与培美曲塞的临床疗效无相关性(无进展生存期:P=0.518,疾病控制率:P=0.631,客观缓解率:P=0.541)。结论:TS基因5’-UTRVNTR多态性与培美曲塞治疗NSCLC疗效可能无相关性。
OBJECTIVE: To investigate the relationship between the VNTR polymorphism of 5’-untranslation region (5’-UTR) and the number of tandem repeat (VNTR) in the gene of thymidylate synthase Pemetrexed treatment of advanced non-small cell lung cancer (non-small cell lung cancer, NSCLC) efficacy correlation. Methods: The clinical parameters of 90 patients with advanced NSCLC were retrospectively analyzed. Peripheral blood samples of patients were collected and DNA was extracted. Combined with short tandem repeat-polymerase chain reaction (STR-PCR) Capillary electrophoresis method to detect TS gene 5’-UTRVNTR polymorphism. Results: There was no correlation between TS gene 5’-UTRVNTR homozygous status (2R / 2R + 3R / 3R) and heterozygous status (2R / 3R + 3R / 4R) The rates of disease control were 64.3% and 67.6% (P = 0.745), objective response rates were 12.5% and 8.8% (P = 0.591) (2R / 3R) and 3R polymorphism (3R / 3R + 3R / 4R) were also not associated with the clinical efficacy of pemetrexed (progression-free survival: P = 0.518, disease control rate: P = 0.631, objective Remission rate: P = 0.541). CONCLUSION: There is no correlation between the 5’-UTRVNTR polymorphism of TS gene and the efficacy of pemetrexed in the treatment of NSCLC.